title: Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects.
abstract: OBJECTIVE
  To examine prospective changes in cardiovascular disease (CVD) and type-2 diabetes risk factors in young adult first episode psychotic (FEP) patients treated with second generation antipsychotic medications.
  
  
  METHODS
  At baseline, fasting serum and anthropometric measures were obtained from 45 FEP patients and 41 healthy adults (controls) of similar age, ethnicity and sex; sixteen of the FEP patients remained on the same antipsychotic medication and were available for a second blood draw at 24 weeks of treatment. Serum was assayed for glucose, insulin, triglycerides, total cholesterol and high and low density lipoproteins (HDL, LDL), adiponectin, leptin, interleukin 6, E-selectin and VCAM-1. Wilcoxon nonparametric tests were used to compare risk markers between the FEP and control group at baseline and to evaluate pre-post treatment changes within the FEP group.
  
  
  RESULTS
  At baseline, the distributions of risk marker values were similar between the two groups and the percentages of FEP patients and healthy controls who were overweight/obese, dyslipidemic, hyperglycemic, and hyperinsulinemic did not differ. At 24 weeks, compared to baseline, FEP patients showed significant increases in BMI (p=0.0002), glucose (p=0.0449), insulin (p=0.0161), cholesterol (p=0.0129), leptin (p=0.0215), and E-selectin (p=0.0195), and a decrease in adiponectin (p=0.0371).
  
  
  CONCLUSIONS
  Among patients with first episode psychosis, 6-month treatment with second generation antipsychotics is associated with the exacerbation of pre-existing and emergence of new CVD and diabetes risk factors.
authors.affiliation: UNC Department of Psychiatry, CB #7160, Chapel Hill, NC 27599-7160, USA. Karen_Graham@med.unc.edu
authors.forename: Karen A
authors.initials: KA
authors.lastname: Graham
authors.forename: Hyunsoon
authors.initials: H
authors.lastname: Cho
authors.forename: Kimberly A
authors.initials: KA
authors.lastname: Brownley
authors.forename: Joyce B
authors.initials: JB
authors.lastname: Harp
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001786:Blood Glucose / Q000187:drug effects; D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000175:diagnosis*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003920:Diabetes Mellitus / Q000139:chemically induced* / Q000175:diagnosis*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007328:Insulin / Q000097:blood; D020738:Leptin / Q000097:blood; D008297:Male; D011618:Psychotic Disorders / Q000097:blood / Q000188:drug therapy; D012189:Retrospective Studies; D012307:Risk Factors; D018709:Statistics, Nonparametric; D014280:Triglycerides / Q000378:metabolism
chemical_list: D014150:Antipsychotic Agents; D001786:Blood Glucose; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D007328:Insulin; D020738:Leptin; D014280:Triglycerides